Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation macimorelin study in pediatric patients with suspected growth hormone deficiency
2018-001988-23Phase 2Completed
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of macimorelin in growth hormone deficiency (GHD) (3 arms), sponsored by COSCIENS Biopharma Inc. Primary endpoints: Safety and tolerability of macimorelin acetate, Pharmacokinetics of macimorelin acetate and 1 more. Started Sep 2018; status: completed.
02
Drugs
macimorelin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2018-001988-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001988-23.